{"id":"wck-2349","_chembl":null,"modality":"Small molecule","_dailymed":null,"_scrapedAt":"2026-03-28T04:50:54.889Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123040,"model":"claude-sonnet-4-5-20250929"},"description":"WCK-2349 is an investigational antibiotic compound developed by Wockhardt currently in Phase 1 clinical trials. The drug is part of Wockhardt's pipeline addressing antimicrobial resistance, though specific molecular targets and therapeutic indications have not been publicly disclosed at this early stage of development.","indications":{"approved":[{"status":"investigational","condition":"Bacterial infections","patientPopulation":"Unknown"}]},"trialDetails":[{"nctId":"NCT04874324","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Oral WCK 2349","status":"COMPLETED","sponsor":"Wockhardt","startDate":"2011-03-17","conditions":"Pharmacokinetics","enrollment":36},{"nctId":"NCT02217930","phase":"PHASE1","title":"Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers","status":"COMPLETED","sponsor":"Wockhardt","startDate":"2014-08","conditions":"Qt Interval, Variation in","enrollment":80},{"nctId":"NCT02244827","phase":"PHASE1","title":"Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment","status":"COMPLETED","sponsor":"Wockhardt","startDate":"2014-09","conditions":"Hepatic Impairment","enrollment":48},{"nctId":"NCT02253342","phase":"PHASE1","title":"Study to Determine and Compare Plasma and Intrapulmonary Pharmacokinetics of WCK 2349 in Healthy Adult Human Subjects","status":"COMPLETED","sponsor":"Wockhardt","startDate":"2014-09","conditions":"Intrapulmonary Pharmacokinetics of WCK 2349","enrollment":30},{"nctId":"NCT01875939","phase":"PHASE1","title":"Phase I, Open Label,Crossover Food-Effect and Absolute Bioavailability Study of WCK2349 and WCK771 in Healthy Adult Human Volunteers","status":"COMPLETED","sponsor":"Wockhardt","startDate":"2013-06","conditions":"Effect of Food","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"WCK-2349","genericName":"WCK-2349","companyName":"Wockhardt","companyId":"wockhardt","firstApprovalDate":"","aiSummary":"WCK-2349 is an oral medication being studied in a Phase-I clinical trial to evaluate its safety, tolerability, and pharmacokinetics. The study is investigating the effects of WCK-2349 on pharmacokinetics, the Qt interval, and its behavior in individuals with hepatic impairment, among other factors.","enrichmentLevel":2,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}